FUJIY - Fujifilm to invest $1.6B to enhance and expand icell culture manufacturing services

• FUJIFILM Corporation ( OTCPK:FUJIY ) announced the investment of $1.6B to enhance and expand the cell culture manufacturing services of it's subsidiary FUJIFILM Diosynth Biotechnologies’ sites in Hillerød, Denmark, and Texas in the United States.
• FUJIFILM Diosynth Biotechnologies is further expanding its capacity with sustainability measures to support large-scale cGMP fed batch production by adding 8 x 20,000L bioreactors and two downstream processing streams in its Hillerød, Denmark facility.
• The additional production capacity will make the Hillerød facility the largest end-to-end CDMO in Europe, offering a total of 20 x 20,000L bioreactors for drug substance production.
• The investment is expected to create ~450 jobs.
• “Fujifilm is further expanding its bio CDMO business with the growth strategy of both capital investment and technological innovation to fulfill rapidly growing demand for high volume production of biopharmaceuticals,” said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. “With this major investment in the large-scale production facility and the deployment of the next generation production technology, we will be the best partner for customers as the premier bio CDMO. Fujifilm ( FUJI ) will, through creation of new value from innovation, contribute to the stable supply of high-quality biopharmaceuticals, and to promoting a healthy society and further growth of healthcare industry.”

For further details see: